Integrating whole-genome sequencing with targeted deep sequencing panels helps to provide a broader and comprehensive view of the genomic landscape in cancer.  The increasing information provided by L-P WGS  can be valuable for monitoring treatment response, detecting disease progression early, and identifying emergent clones associated with therapeutic resistance.